{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Havens PL"],"funding":["NICHD NIH HHS","NCATS NIH HHS","NCRR NIH HHS","PHS HHS"],"pagination":["5619-28"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3811269"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["57(11)"],"pubmed_abstract":["Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by an unknown mechanism(s). Data are limited on tenofovir pharmacokinetics and these effects. Using baseline data from a multicenter study of HIV-infected youth on stable treatment with regimens containing TDF (n = 118) or lacking TDF (n = 85), we measured cross-sectional associations of TDF use with markers of renal function, vitamin D-calcium-parathyroid hormone balance, phosphate metabolism (tubular reabsorption of phosphate and fibroblast growth factor 23 [FGF23]), and bone turnover. Pharmacokinetic-pharmacodynamic associations with plasma tenofovir and intracellular tenofovir diphosphate concentrations were explored among those receiving TDF. The mean age was 20.9 (standard deviation [SD], 2.0) years; 63% we"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?"],"pmcid":["PMC3811269"],"funding_grant_id":["M01 RR010710","U01 HD 040474","U01 A1068632","UL1 TR002319","M01 RR020359","U01 HD 040533","UL1 RR024134","UL1 RR025014","U01 HD040474","M01 RR000188","U01 HD040533","UL1 RR024131","U01 HD040497","UL1 TR001082"],"pubmed_authors":["Kapogiannis BG","Havens PL","Flynn PM","Liu N","Woodhouse LR","Gordon CM","Van Loan MD","Lujan-Zilbermann J","Pan CG","Stephensen CB","Baker A","Hazra R","Bethel J","Wilson CM","Kiser JJ","Rutledge B","Mulligan K","Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team"],"additional_accession":[]},"is_claimable":false,"name":"Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?","description":"Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by an unknown mechanism(s). Data are limited on tenofovir pharmacokinetics and these effects. Using baseline data from a multicenter study of HIV-infected youth on stable treatment with regimens containing TDF (n = 118) or lacking TDF (n = 85), we measured cross-sectional associations of TDF use with markers of renal function, vitamin D-calcium-parathyroid hormone balance, phosphate metabolism (tubular reabsorption of phosphate and fibroblast growth factor 23 [FGF23]), and bone turnover. Pharmacokinetic-pharmacodynamic associations with plasma tenofovir and intracellular tenofovir diphosphate concentrations were explored among those receiving TDF. The mean age was 20.9 (standard deviation [SD], 2.0) years; 63% we","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Nov","modification":"2025-04-22T04:48:31.726Z","creation":"2019-03-27T01:17:45Z"},"accession":"S-EPMC3811269","cross_references":{"pubmed":["24002093"],"doi":["10.1128/AAC.01096-13","10.1128/aac.01096-13"]}}